Sec Form 4 Filing - SVLSF IV, LLC @ KalVista Pharmaceuticals, Inc. - 2019-03-29

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person SVLSF IV, LLC 2. Issuer Name and Ticker or Trading Symbol KalVista Pharmaceuticals, Inc. [ KALV] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900 3. Date of Earliest Transaction (MM/DD/YY) 03/29/2019 (Street) BOSTON, MA02108 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 03/29/2019 S 34,133 D $ 28.396 ( 1 ) 1,780,986 D ( 2 ) ( 3 ) Common Stock 03/29/2019 S 969 D $ 28.396 ( 1 ) 50,562 D ( 3 ) ( 4 ) Common Stock 04/01/2019 S 51,373 D $ 27.6582 ( 5 ) 1,729,613 D ( 2 ) ( 3 ) Common Stock 04/01/2019 S 1,458 D $ 27.6582 ( 5 ) 49,104 D ( 3 ) ( 4 ) Common Stock 04/02/2019 S 8,888 D $ 28.7638 ( 6 ) 1,720,725 D ( 2 ) ( 3 ) Common Stock 04/02/2019 S 253 D $ 28.7638 ( 6 ) 48,851 D ( 3 ) ( 4 )

Table II - Derivative Securities Acquired, Dispo sed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other SVLSF IV, LLC ONE BOSTON PLACE 201 WASHINGTON STREET, SUITE 3900 BOSTON, MA02108 X SV Life Sciences Fund IV (GP), L.P. ONE BOSTON PLACE 201 WASHINGTON STREET, SUITE 3900 BOSTON, MA02108 X SV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P. ONE BOSTON PLACE 201 WASHINGTON STREET, SUITE 3900 BOSTON, MA02108 X SV LIFE SCIENCES FUND IV, L.P. ONE BOSTON PLACE 201 WASHINGTON STREET, SUITE 3900 BOSTON, MA02108 X Signatures /s/ Brent Faduski 04/02/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.62 to $29.13, inclusive. The Reporting Persons undertake to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. ( 2 )These shares are held directly by SVLS IV LP. ( 3 )SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliares. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. SVLS IV GP, the general partner of the Funds, may be deemed to share voting and dispositive power over the shares held by the Funds. SVLS IV GP disclaims beneficial ownership of shares held by the Funds, except to the extent of any pecuniary interest therein. SVLSF IV, LLC, the general partner of SVLS IV GP. may be deemed to share voting and dispositive power over the shares held by the Funds. SVLSF IV, LLC. disclaims beneficial ownership of shares held by the Funds except to the extent of any pecuniary interest therein. ( 4 )These shares are held directly by Strategic Partners. ( 5 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 to $28.78, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. ( 6 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.53 to $29.14, inclusive. The Reporting Persons undertake to provide to Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks: This statement is filed by: (i) SV Life Sciences Fund IV. L.P. ("SVLS IV LP") and SV Life Sciences Fund IV Strategic Partners, L.P. ("Strategic Partners"), each a Delaware limited partnership and direct owners of the shares of Common Stock of the Issuer (together, the "Shares"): (ii) SV Life Sciences Fund IV (GP), L.P., a Delaware limited partnership ("SVLS IV GP") and general partner of SVLS IV LP and Strategic Partners; and (iii) SVLSF IV, LLC, a Delaware limited liability company and general partner of SVLS IV GP. Each of SVLS IV LP, Strategic Partners, SVLS IV GP and SVLSF IV, LLC are sometimes individually referred to herein as a "Reporting Person" and collectively as the "Reporting Persons."

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.